ReviewCurrent oncology reports2017
Polypharmacy in the Geriatric Oncology Population.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Applying the Bradford Hill Criteria to Assess the Independent Causal Roles of Aging and Medication in Frailty Progression: A Systematic Review.Drugs & aging · 2026Pooled it
- Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Complementary and alternative medicine use among elderly cancer patients: a cross-sectional study in South Korea.Frontiers in oncology · 2026Article
- Artificial intelligence-driven risk prediction of polypharmacy in older adults: current advances, clinical applications, and future perspectives.Frontiers in public health · 2026Review
- Complementary and Alternative Medicine (CAM) Use among Elderly Cancer Patients: A cross-sectional study in South Korea.Research square · 2025Article
- Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer.Cancers · 2024Article
- Care Delivery Interventions for Individuals with Cancer: A Literature Review and Focus on Gastrointestinal Malignancies.Healthcare (Basel, Switzerland) · 2023Review
- Multicenter prospective observational study on hospital pharmacist interventions to reduce inappropriate medications.Frontiers in pharmacology · 2023Article
- Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies.Drugs & aging · 2021Review
- Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review.Therapeutics and clinical risk management · 2020Review
- Cancer statistics for adults aged 85 years and older, 2019.CA: a cancer journal for clinicians · 2019Article
- A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan.Journal of pharmaceutical health care and sciences · 2019Article
- Influence of Concomitant Polypharmacy on Docetaxel-induced Febrile Neutropenia.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review explores the multiple definitions, epidemiology, and impact of polypharmacy in geriatric oncology patients. Risk factors and clinical implications of polypharmacy are delineated and potential clinical approaches to reduce polypharmacy are reviewed. RECENT
findingsMost sources currently define polypharmacy as the administration of multiple medications that are non-essential, unnecessary, duplicative, or ineffective. Possible risk factors associated with polypharmacy in geriatric cancer patients include comorbid conditions, prescribing cascades, and hospitalization. Consequences of polypharmacy in this population include adverse drug events, drug-drug interactions, reduced adherence, frailty, and increased morbidity. Clinical approaches to the reduction of polypharmacy include thorough medication histories and an interprofessional team approach to care. Polypharmacy is common and has a direct clinical impact on geriatric oncology patients. There is a clear deficit in our understanding of the scope and impact of polypharmacy in this population and only limited evaluation of various interventions exist. The paucity of information is at least partially linked to the consistent exclusion of older adults in cancer studies and the complex interaction between polypharmacy and potential morbidities/mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.